TABLE 2

Regimen received and treatment outcomes among patients on standard and prolonged treatment with bedaquiline

Bedaquiline <190 daysBedaquiline >190 daysp-value#
Patients n8330
Regimen duration
Median (IQR) total treatment duration, months23.7 (20.7–24.0)24.2 (23.8–24.9)<0.01
Median (IQR) treatment duration with bedaquiline, months5.5 (5.4–5.6)8.0 (7.3–9.2)<0.01
Median (IQR) treatment duration with linezolid, months23.5 (20.1–24.0)24.1 (23.7–24.4)<0.01
Median (IQR) treatment duration with injectables, months+5.3 (5.3–21.2)13.8 (10.7–24.2)0.02
Treatment outcomes
Number with treatment success77 (92.8)29 (96.7)0.75
Number with failure1 (1.2)0 (0)1
Number dying during treatment3 (3.6)1 (3.3)1
Number lost to follow-up2 (2.4)0 (0)0.96
Regimen receivedInitialAdded during treatmentInitialAdded during treatment
Number of drugs in initial regimen, median (IQR)6 (5–6)6 (6–6)0.80
Included moxifloxacin or levofloxacin or gatifloxacin11 (13.3)43 (51.8)0 (0)15 (50)0.08
Included linezolid83 (100)0 (0)29 (96.7)1 (3.3)0.59
Included clofazimine80 (96.4)1 (1.2)27 (90)2 (6.7)0.39
Included terizidone82 (98.8)0 (0)28 (93.3)2 (6.7)0.35
Included amikacin or capreomycin or kanamycin32 (38.6)6 (7.2)14 (46.7)10 (33.3)0.58
Included pyrazinamide54 (65.1)2 (2.4)23 (76.7)0 (0)0.35
Included imipenem/cilastatin with amoxicillin and clavulanic acid42 (50.6)2 (2.4)16 (53.3)7 (23.3)0.97
Included ethionamide or prothionamide8 (9.6)8 (9.6)2 (6.7)3 (10)0.91

Data reported as n (%) unless otherwise specified. #: the following tests were used to calculate p-value: for medians Kruskal–Wallis test; for proportions Chi square test; for rates exact Fisher two-sided test. For the regimen received, p-value only refers to initial regimen. : all patients received linezolid during treatment. +: only if received injectables ever during treatment (n=35 bedaquiline 6 months; n=20 bedaquiline >6 months; n=55 overall).